NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
Clinical Trials
8 trialsNCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT01284920 2024-11-21
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Astellas Pharma Inc
Phase 1/2 Completed
NCT02555189 2024-05-13
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Completed
NCT03437941 2023-05-06
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Corcept Therapeutics
Phase 1/2 Completed
NCT02012296 2022-07-13
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
University of Chicago
Phase 1/2 Completed
NCT02711956 2021-11-30
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
Phase 1/2 Completed